111 related articles for article (PubMed ID: 25353069)
41. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
42. Cutaneous complications among i.v. buprenorphine users.
Ho RC; Ho EC; Mak A
J Dermatol; 2009 Jan; 36(1):22-9. PubMed ID: 19207433
[TBL] [Abstract][Full Text] [Related]
43. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
[TBL] [Abstract][Full Text] [Related]
44. Drugs approved for opiate dependence.
FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
[No Abstract] [Full Text] [Related]
45. [Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians].
De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A27-32. PubMed ID: 10855374
[TBL] [Abstract][Full Text] [Related]
46. Favorable mortality profile of naltrexone implants for opiate addiction.
Reece AS
J Addict Dis; 2010 Jan; 29(1):30-50. PubMed ID: 20390697
[TBL] [Abstract][Full Text] [Related]
47. [High-dose buprenorphine prescription in southern France from 1999 to 2001].
Mancini J; Thirion X; Masut A; Ronflé E; Coudert C; Pradel V; Frauger E; Micallef J
Ann Med Interne (Paris); 2003 Jun; 154 Spec No 1():S7-14. PubMed ID: 12910029
[TBL] [Abstract][Full Text] [Related]
48. Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy.
Seet RC; Lim EC
Ann Emerg Med; 2006 Apr; 47(4):396-7. PubMed ID: 16546629
[No Abstract] [Full Text] [Related]
49. Double trouble-pregnancy and antagonist treatment in opioid dependence; two contentious issues needing further consideration and research.
Clark N; Verster A
Addiction; 2013 Feb; 108(2):253-5. PubMed ID: 23331880
[No Abstract] [Full Text] [Related]
50. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
[TBL] [Abstract][Full Text] [Related]
51. Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
Winstock AR; Lea T; Sheridan J
Drug Alcohol Rev; 2008 Jul; 27(4):393-7. PubMed ID: 18584389
[TBL] [Abstract][Full Text] [Related]
52. Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis.
Andresz V; Marcantoni N; Binder F; Velten M; Alt M; Weber JC; Stephan D
Addiction; 2006 Sep; 101(9):1347-51. PubMed ID: 16911735
[TBL] [Abstract][Full Text] [Related]
53. Should Buprenorphine Induction Dosing Be Lower for the Elderly Population With Opioid Use Disorder? A Case of Buprenorphine-Induced Hemodynamic Instability.
Chaparro A; Ravishankar DA; Sethi R
Prim Care Companion CNS Disord; 2020 Sep; 22(5):. PubMed ID: 32910846
[No Abstract] [Full Text] [Related]
54. Magnetocardiographic identification of prolonged fetal corrected QT interval in women receiving treatment for opioid use disorder.
Bolin EH; Escalona-Vargas D; Daily JA; Siegel ER; Lowery CL; Coker J; Stowe ZN; Eswaran H
J Obstet Gynaecol Res; 2019 Oct; 45(10):1989-1996. PubMed ID: 31297963
[TBL] [Abstract][Full Text] [Related]
55. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Reece AS
J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
[TBL] [Abstract][Full Text] [Related]
56. [Buprenorphine as a new alternative for detoxification of heroin addicts. It causes only mild withdrawal problems, abating quickly].
Blennow G; Fergusson A; Medvedeo A
Lakartidningen; 2000 Apr; 97(15):1830-3. PubMed ID: 10815411
[TBL] [Abstract][Full Text] [Related]
57. Crushing buprenorphine tablets.
Muhleisen P; Spence J; Nielsen S
Drug Alcohol Rev; 2003 Dec; 22(4):471-2. PubMed ID: 14660137
[No Abstract] [Full Text] [Related]
58. Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.
Dakwar E; Kleber HD
J Subst Abuse Treat; 2015 Jun; 53():60-3. PubMed ID: 25819700
[TBL] [Abstract][Full Text] [Related]
59. Myocardial infarction associated with buprenorphine.
Cracowski JL; Mallaret M; Vanzetto G
Ann Intern Med; 1999 Mar; 130(6):536; author reply 536-7. PubMed ID: 10075626
[No Abstract] [Full Text] [Related]
60. Treatment of buprenorphine precipitated withdrawal: a case report.
Jutras-Aswad D; Widlitz M; Scimeca MM
Am J Addict; 2012; 21(5):492-3. PubMed ID: 22882402
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
